Biography
Andrew Cauchi is counsel in Weil’s Securities Litigation practice, where he focuses on securities fraud class action litigation, shareholder derivative suits, litigation arising from mergers and acquisitions, internal investigations, and SEC and other governmental inquiries and investigations.
Andrew’s recent experience includes serving on Weil teams representing:
- Willis Towers Watson plc and certain former directors of Towers Watson & Co. and Willis Group Holdings in multi-jurisdictional securities and fiduciary duty litigation related to Willis’s merger with Towers Watson.
- A global investment bank in connection with a number of regulatory investigations.
- Lehman Brothers and the Archstone-Smith REIT, among 20 other defendants, in securing summary judgment on all claims in a $4 billion investor class action arising from one of the largest REIT going-private transactions in history. The Tenth Circuit later affirmed.
- Sanofi in connection with litigation in the Southern District of New York relating to the issuance of contingent value rights in connection with the company’s acquisition of Genzyme.
- Pilgrim’s Pride, the second largest poultry producer in the U.S., in securities class action and shareholder derivative actions related to alleged industry-wide price fixing.
Andrew maintains an active pro bono practice, including as a member of the Weil team that won asylum for a Tibetan Buddhist refugee who was fleeing persecution by a foreign government.
Andrew was honored in the 2021 and 2022 editions of Best Lawyers: Ones to Watch for securities litigation. In the second half of 2019, he participated in Morgan Stanley’s attorney secondment program, where he worked in Morgan Stanley Smith Barney’s Branch Advisory Legal group.
Andrew received his J.D. from St. John’s University School of Law and his B.A. from Lehigh University. He was a member of the St. John’s Law Review.